Clinical trial
Rt-PA in the Treatment of Acute Ischemic Stroke
NCT00153036 · Boehringer Ingelheim, Industry · Completed
Key facts
| NCT number | NCT00153036 |
|---|---|
| Title | Rt-PA in the Treatment of Acute Ischemic Stroke |
| Official title | ECASS III - European Cooperative Acute Stroke Study III: A Placebo Controlled Trial of Alteplase (Rt-PA) in Acute Ischemic Hemispheric Stroke Where Thrombolysis is Initiated Between 3 and 4 Hours 30 Minutes After Stroke Onset |
| Lead sponsor | Boehringer Ingelheim, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Cerebrovascular Accident |
| Intervention type | Drug |
| Interventions | rt-PA 0.9 mg/kg verum or placebo Intravenous |
| Enrollment | 821 |
| Start date | Apr 1, 2003 |
| Primary completion | Feb 1, 2008 |
| First posted | Sep 12, 2005 |
| Last update posted | May 16, 2014 |
| Countries | Austria, Belgium, Czechia, Denmark, Finland, France, Germany, Greece, Hungary, Italy, Netherlands, Norway and 7 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: